|
ATP5G3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.798000E-04 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.837700E-04 |
| Normal-vs-Stage2 |
2.865800E-01 |
| Normal-vs-Stage3 |
1.53205999999795E-05 |
| Normal-vs-Stage4 |
4.2008999945331E-08 |
| Stage1-vs-Stage2 |
6.881700E-03 |
| Stage1-vs-Stage3 |
2.375600E-01 |
| Stage1-vs-Stage4 |
1.119050E-03 |
| Stage2-vs-Stage3 |
2.459000E-03 |
| Stage2-vs-Stage4 |
1.624540E-04 |
| Stage3-vs-Stage4 |
3.045800E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.72760000003181E-06 |
| Normal-vs-AfricanAmerican |
3.308400E-02 |
| Normal-vs-Asian |
1.298170E-03 |
| Caucasian-vs-AfricanAmerican |
4.249200E-01 |
| Caucasian-vs-Asian |
8.036600E-01 |
| AfricanAmerican-vs-Asian |
5.856200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.264500E-03 |
| Normal-vs-Female |
5.442100E-04 |
| Male-vs-Female |
9.029200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.366500E-04 |
| Normal-vs-Age(41-60Yrs) |
4.397600E-04 |
| Normal-vs-Age(61-80Yrs) |
2.817000E-01 |
| Normal-vs-Age(81-100Yrs) |
3.302800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.634000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.325600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.665700E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.627600E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.397700E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.299100E-03 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.727900E-02 |
| Classical-VS-Follicular |
1.70330000004437E-06 |
| Classical-VS-Other |
6.323000E-01 |
| Classical-VS-Normal |
9.7663999998332E-08 |
| Tall-VS-Follicular |
9.17729999772021E-08 |
| Tall-VS-Other |
4.089000E-01 |
| Tall-VS-Normal |
2.07189999601454E-08 |
| Follicular-VS-Other |
2.191600E-01 |
| Follicular-VS-Normal |
2.867000E-01 |
| Other-VS-Normal |
1.172160E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.874390E-02 |
| Normal-vs-N1 |
1.37229999586097E-08 |
| N0-vs-N1 |
1.59570000002329E-06 |
|
|
